Cargando...
Euglycemic DKA (euDKA) as a presentation of COVID‐19
COVID‐19 in the setting of SGLT2 inhibitor use may precipitate euglycemic DKA separate from known acute viral illness and dehydration precipitants. There should be consideration of proactive discontinuation of these medications in these patients.
Gardado en:
| Publicado en: | Clin Case Rep |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7753533/ https://ncbi.nlm.nih.gov/pubmed/33362928 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.3540 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|